Product Description
Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)
Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia
Known Adverse Events: Insomnia | Anemia | Febrile Neutropenia | Neutropenia | Constipation | Diarrhea
Company: Premier Inc
Company Location:
Company CEO:
Additonal Commercial Interests: Pfizer
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Netherlands, Poland, Puerto Rico, Russia, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|T-Cell Peripheral Lymphoma
Phase 2: Desmoplastic Small Round Cell Tumor|Diffuse Large B-Cell Lymphoma|Osteosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Rhabdomyosarcoma|Sarcoma, Ewing|Small Cell Sarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |
|
| NCT06709495 | P2 |
Not yet recruiting |
Desmoplastic Small Round Cell Tumor|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Osteosarcoma|Rhabdomyosarcoma|Small Cell Sarcoma|Peripheral Neuroectodermal Tumors, Primitive |
2028-11-01 |
|
| RG1124788 | P2 |
Not yet recruiting |
Unknown |
2027-12-31 |
|
| GO43075 | P2 |
Active, not recruiting |
Diffuse Large B-Cell Lymphoma |
2025-06-01 |